Search: WFRF:(Follin Cecilia)
> (2020-2023) >
Key Device Attribut...
Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours
-
- Jørgensen, Jens Otto Lunde (author)
- Aarhus University Hospital
-
- de Herder, Wouter W. (author)
- Erasmus University Medical Center
-
- Martin, Wendy A. (author)
- King's College Hospital
-
show more...
-
- Kolarova, Teodora (author)
- International Neuroendocrine Cancer Alliance - INCA
-
- Marks, Muriël (author)
- World Alliance of Pituitary Organizations (WAPO)
-
- Follin, Cecilia (author)
- Lund University,Lunds universitet,Barns och familjers hälsa,Forskargrupper vid Lunds universitet,Medicin/akutsjukvård, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Endokrin,Sena effekter efter barncancerbehandling,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Child and Family Health,Lund University Research Groups,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Endocrine,Late effects after childhood cancer treatment,LUCC: Lund University Cancer Centre,Other Strong Research Environments
-
- Geilvoet, Wanda (author)
- Erasmus University Medical Center
-
- Melmed, Shlomo (author)
- Cedars-Sinai Medical Center
-
show less...
-
(creator_code:org_t)
- 2023
- 2023
- English 14 s.
-
In: Advances in Therapy. - 0741-238X. ; 40:10, s. 4675-4688
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Introduction: People living with acromegaly and neuroendocrine tumours (NETs) may be treated with injectable somatostatin receptor ligands (SRLs), administered by either a caregiver or as self-injection via a proprietary or generic device. Injection device attributes that contribute to ease of use and storage, minimise preparation requirements, and reduce injection pain are associated with improved adherence and more favourable therapeutic outcomes. The aim of this study was to assess current opinion surrounding favourable SRL device attributes for people living with acromegaly and NETs as well as that of their caregivers. Methods: Participants (healthcare professionals [HCPs] and patients/non-HCP caregivers) from 11 countries were invited to answer survey questions related to their demographic, experience, and preferences as they relate to the real-world use of injectable SRL devices. Questions were developed based on review of available literature and meetings with a Scientific Committee. Results: Device attributes preferred by the patient/non-HCP caregiver group (n = 211) included confidence that the correct drug amount is delivered (76%), quick administration with minimal pain/discomfort (68%), and device safety (needle-safety and low risk of contamination; 53%). Device attributes preferred by HCPs (n = 52) were quick administration with minimal pain/discomfort (69%), correct use is easy to learn, confidence in handling the device (63%), and confidence that the correct drug amount is delivered (62%). Conclusion: The results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Samhällsfarmaci och klinisk farmaci (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Social and Clinical Pharmacy (hsv//eng)
Keyword
- Acromegaly
- NETs
- Neuroendocrine tumours
- Somatostatin receptor ligand
- SRL
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database